Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: A focused healthcare company and world leader in diabetes care, with additional leading positions in hemostasis management, growth hormone therapy, and hormone replacement therapy. The company operates in approximately 180 countries with over 18,000 employees. It maintains a two-tier board structure under Danish law.
Key Financial Metrics
Profitability: Net profit increased by 22% in 2002 compared to 2001 on a US GAAP basis. The operating profit margin improved to 23.7% in 2002 (up from 21.5% in 1998). Return on invested capital (ROIC) after tax reached 20% in 2002.
Cash Flow: Free cash flow increased significantly to DKK 497 million in 2002, up from DKK 186 million in 2001. This improvement was driven by a DKK 561 million increase in cash flow from operating activities, largely due to a decrease in trade debtors.
Liquidity and Debt:
- Financial Resources: DKK 9,195 million as of December 31, 2002 (comprising DKK 1,234 million in cash/cash equivalents and DKK 7,961 million in undrawn committed credit facilities).
- Long-term Debt: DKK 824 million as of December 31, 2002.
- Credit Facilities: Includes a USD 600 million facility maturing in 2004 and a EUR 500 million facility maturing in 2007.
Capital Expenditure: Net capital expenditure for property, plant, and equipment was DKK 4.0 billion in 2002, reflecting significant investment in production capacity for diabetes care and NovoSeven®.
Research & Development: Expenditures totaled DKK 4,139 million (16% of net turnover) in 2002.
Material Changes vs. Prior Period
- Acquisitions: Completed the acquisition of Biobrás, a Brazilian diabetes care company, making it a wholly-owned subsidiary. The total purchase price was BRL 133.5 million (DKK 380 million).
- Investment Gains: Realized an unrealized pretax capital gain of DKK 236 million following the IPO of ZymoGenetics, Inc., in which Novo Nordisk holds a 39% stake.
- Product Development: Suspended phase 3 trials of ragaglitazar (NN622) due to tumor findings in animal studies. Decided to proceed with the development of NN2344, another insulin sensitizer.
- Share Buy-back: Announced a new share buy-back scheme of DKK 2 billion in August 2002, increasing the holding of treasury shares to almost 3%.
- Revenue Mix: Diabetes care accounted for 70% of total consolidated sales in 2002. Hemostasis management (NovoSeven®) accounted for 14%.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance:
- Management expects R&D spending to remain between 16% and 17% of net turnover.
- Capital expenditure is expected to be DKK 3.5 billion in 2003, with a decrease anticipated in 2004.
- Dividend Proposal: The Board proposed a dividend of DKK 3.60 per share at the March 2003 Annual General Meeting.
Risk Factors:
- Market Risks: High exposure to diabetes care (70% of sales); potential impact from new competitor treatments or oral antidiabetic drugs. Parallel importation from low-price markets poses a threat to profitability.
- Currency Risks: Significant exposure to USD, JPY, and GBP. A 5% movement in these rates is estimated to impact operating profit by DKK 160 million (USD), DKK 130 million (JPY), and DKK 75 million (GBP) annually.
- Development Risks: Uncertainty in clinical development and regulatory approvals for new drug candidates.
- Patent Expirations: Activelle/Activella patents expire in the US in 2006 and in Europe between 2004 and 2009. NovoSeven® patent expires in Japan in 2008.
Legal Proceedings:
- Poland Customs: Authorities investigated potential misstatement of customs values for 1999, claiming approximately DKK 130 million. Management believes it acted in compliance, but legal action remains a risk.
- US Litigation: Settled a patent infringement case against Becton Dickinson in October 2002 via a cross-license agreement (financial terms undisclosed).
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of the 70% revenue reliance on diabetes care and the competitive landscape for insulin analogues.
- Currency Sensitivity: Assess the impact of DKK/USD/JPY/GBP exchange rate fluctuations on future operating margins, given the significant hedging exposure.
- R&D Pipeline: Monitor the progress of NN2344 and the impact of the discontinued NN622 program on future growth prospects.
- Regulatory Environment: Track potential price decreases mandated by governments in major markets (Japan, North America, Europe) and the outcome of the Polish customs investigation.
- Capital Allocation: Review the execution of the DKK 3.5 billion investment plan for 2003 and the completion of the DKK 2 billion share buy-back scheme.